Atractylenolide III, a sesquiterpenoid, induces apoptosis in human lung carcinoma A549 cells via mitochondria-mediated death pathway.

Pharmacological agents that are safe and can sensitize the lung cancer are urgently required. We investigated whether Atractylenolide III (ATL-III), the major component of Atractylodes rhizome can induce apoptosis of the lung carcinoma cells. ATL-III inhibited cell growth, increased lactate dehydrogenase release and modulated cell cycle on human lung carcinoma A549 cells. ALT-III induced the activation of caspase-3 and caspase-9 and cleavage of poly-(ADP)-ribose polymerase. ATL-III induced the release of cytochrome c, upregulation of bax expression, and translocation of apoptosis-inducing factor. In addition, ATL-III inhibited the proliferation and capillary tube formation of human umbilical vein endothelial cells. These data indicate that ATL-III is a potential candidate for treatment of human lung carcinoma.

[1]  T. Fan,et al.  Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. , 1995, Trends in pharmacological sciences.

[2]  A. Reynolds,et al.  Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer , 2010, Dose-response : a publication of International Hormesis Society.

[3]  L. Kirshenbaum,et al.  Mitochondria-assisted cell suicide: a license to kill. , 2003, Journal of molecular and cellular cardiology.

[4]  Jong-Suk Kim,et al.  Induction of apoptosis by takrisodokyeum through generation of hydrogen peroxide and activation of caspase-3 in HL-60 cells. , 2003, Life sciences.

[5]  M. Gordon,et al.  Tumor angiogenesis and novel antiangiogenic strategies , 2010, International journal of cancer.

[6]  M. Su,et al.  Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. , 1995, Science.

[7]  Ruedi Aebersold,et al.  Molecular characterization of mitochondrial apoptosis-inducing factor , 1999, Nature.

[8]  Lang-chong He,et al.  Atractylenolide I and atractylenolide III inhibit Lipopolysaccharide‐induced TNF‐α and NO production in macrophages , 2007, Phytotherapy research : PTR.

[9]  K. Schulze-Osthoff,et al.  Many cuts to ruin: a comprehensive update of caspase substrates , 2003, Cell Death and Differentiation.

[10]  T. Dawson,et al.  Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. , 2004, Trends in pharmacological sciences.

[11]  Claus Belka,et al.  Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis , 2000, Oncogene.

[12]  Genhong Cheng,et al.  The signaling adaptors and pathways activated by TNF superfamily. , 2003, Cytokine & growth factor reviews.

[13]  Guido Kroemer,et al.  Mitochondrio‐nuclear translocation of AIF in apoptosis and necrosis , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[15]  C. Cotman,et al.  DNA Damage and Activated Caspase-3 Expression in Neurons and Astrocytes: Evidence for Apoptosis in Frontotemporal Dementia , 2000, Experimental Neurology.

[16]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[17]  C. Borner.  The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. , 2003, Molecular immunology.

[18]  E. Woodle,et al.  Programmed cell death. , 1998, Transplantation.

[19]  Li Zhu,et al.  Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. , 1998, Cancer research.

[20]  A. Mantovani,et al.  Molecular mechanisms of blood vessel formation. , 1997, Trends in biochemical sciences.

[21]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[22]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[23]  F. Khuri,et al.  Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. , 2004, Journal of the National Cancer Institute.

[24]  G. Pfeifer,et al.  Second-hand smoke and human lung cancer. , 2008, The Lancet Oncology.

[25]  K. Ahn,et al.  Ocimum sanctum induces apoptosis in A549 lung cancer cells and suppresses the in vivo growth of lewis lung carcinoma cells , 2009, Phytotherapy research : PTR.

[26]  Langchong He,et al.  Anti-inflammatory components isolated from Atractylodes macrocephala Koidz , 2008, Natural product research.

[27]  M. Nair,et al.  From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer , 2006, Expert opinion on therapeutic targets.

[28]  T. Chittenden,et al.  Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Chi-Hung Lin,et al.  BPR0C261 is a novel orally active antitumor agent with antimitotic and anti‐angiogenic activities , 2011, Cancer science.

[30]  A. Dove.  Making a living out of the art of dying , 2001, Nature Biotechnology.

[31]  K. H. Jones,et al.  γ-Tocopheryl quinone induces apoptosis in cancer cells via caspase-9 activation and cytochrome c release , 2003 .